Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson ' s and Alzheimer ' s Disease

Microglia activation leads to inflammation mediated dopaminergic degeneration in the brain of patients with Parkinson and Alzheimer ' s Disease. Thus Identification of drugs that reduce microglia activation could prevent or reverse neuronal degeneration in these diseases and other degenerative CNS disorders.This invention describes small-peptide and non-peptide molecules that inhibit microglia activation and prevent neuronal degeneration with a bi-modal dose response curve. The non-peptide compounds have also been shown to prevent dopamine neuronal degeneration in animal models. This invention provides compositions and methods for inhibiting inflammatory mechanisms and treating inflammation-related condition by administering ultra-low (femto-molar) doses of at least one compound of the invention. These compounds include morphinans, opioid peptides, and the tripeptide GGF.IC: NIEHSNIH Ref. No.: E-130-2004-0TAB No: TAB-1010Advantages: These compounds are active at ultra-low concentrations.Applications: Therapeutic treatment of Parkinson, Alzheimers and other degenerative CNS disorders.Development Status: Early-stagePre-clinicalIn vitro data availableIn vivo data available (animal)Provider Technology ID: 1010Updated On: Sep 3, 2020Date Published: Thursday, September 3, 2020Patent Application: PCT/US2005/1669114/323,55713/324,87660/570,56611/596,296Patent Authority: PCTUSUSUSUSPatent Number: 9,498,5118,796,3028,088,787Le...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research